Loading
A phase 3 trial of Belantamab mafodotin, Daratumumab, Bortezomib in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting.
Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT06868667 by GlaxoSmithKline, with 24 participants enrolled, started 2021-07-28 and due to reach its primary completion in 2024-04-03. Interventions recorded: Belantamab mafodotin, Daratumumab, Bortezomib, Dexamethasone. Conditions listed: Multiple Myeloma. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
24 enrolled.
The median and upper limit of 95% Confidence Interval were not estimable due to the length of follow-up in assessing the number of events.; Figures from the ClinicalTrials.gov results section (first posted 2025-05-09), not from a publication · 95% CI 4.9 to NA
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free Survival (PFS)primary | Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) | 10 | The median and upper limit of 95% Confidence Interval were not estimable due to the length of follow-up in assessing the number of events.; Figures from the ClinicalTrials.gov results section (first posted 2025-05-09), not from a publication | 0.4 (0.11 to 1.52) | - | link |
| Daratumumab + Bor + Dex | 14 | 11.1 months |
Shares Belantamab mafodotin, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Bortezomib.
Shares Belantamab mafodotin, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, GSK.
Shares Belantamab mafodotin, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, GSK.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Bortezomib, Dexamethasone.
Shares Belantamab mafodotin, Bortezomib, GSK, Dexamethasone.
Shares Belantamab mafodotin, Antiemetics for chemotherapy-induced nausea and vomiting, GSK, Dexamethasone.
Shares Belantamab mafodotin, Antiemetics for chemotherapy-induced nausea and vomiting, GSK, Dexamethasone.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Bortezomib, Dexamethasone.